Posted by Michael Wonder on 20 May 2022
Viatris and Biocon Biologics launch Abevmy (bevacizumab), their third oncology siosimilar, in Canada
19 May 2022 - Viatris and Biocon Biologics announced today that Abevmy (bevacizumab) is now available in Canada.
Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin (bevacizumab) and has been approved by Health Canada across four oncology indications.
The Viatris Advocate program is also now available for Abevmy. The program offers support and resources for patients, their caregivers and their healthcare providers.
